ConductScience.org, home

Paper8325342

Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA.

Martinon F and 7 others. Eur J Immunol, 1993. Cited by 361 papers, by iCite.

Cite this record

ConductScience Library. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Papers, record 8325342. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8325342

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA.
PubMed
Journal
Eur J Immunol
PubMed
Year
1993
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
361
iCite
Relative citation ratio, by iCite
6.38
iCite
Revised in PubMed
2006-11-20
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Martinon FF
2Krishnan SS
3Lenzen GG
4Magné RR
5Gomard EE
6Guillet JGJ G
7Lévy JPJ P
8Meulien PP

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antigens, ViralMajor topic
Influenza A virusMajor topic
NucleoproteinsMajor topic
RNA, MessengerMajor topic
T-Lymphocytes, CytotoxicMajor topic
Viral Core ProteinsMajor topic
Animals
Cytotoxicity, Immunologic
Immunity, Cellular
Liposomes
Mice
Mice, Inbred Strains
Nucleocapsid Proteins
Vaccines, Synthetic
Viral Vaccines

Source PubMed

Download CSV of topics

Cited by228

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 361 citations.

PMIDTitleJournalYearIn PapersSource
42853631mRNA-based therapies: From molecular discovery to clinical revolution.Genet Mol Biol2026https://conductscience.org/library/papers/42853631PubMed
42782773mRNA Vaccines as Novel Immunotherapeutic Approaches in Gastrointestinal Cancers.Cells2026https://conductscience.org/library/papers/42782773PubMed
42746222Target, silence, replace: a review on RNA-based drugs in modern medicine.Front Cell Dev Biol2026https://conductscience.org/library/papers/42746222PubMed
42728430Structural evolution of ionizable lipids for nucleic acid delivery.Nat Rev Chem2026https://conductscience.org/library/papers/42728430PubMed
42651807Engineering the Future of Precision Medicine: A Comprehensive Guide to RNA Therapeutics.Curr Issues Mol Biol2026https://conductscience.org/library/papers/42651807PubMed
42514871Analytical Characterization and Stability Assessment of RNA-Based Vaccines.Pharmaceutics2026https://conductscience.org/library/papers/42514871PubMed
42380588Advancements in RNA-based therapies from bench to bedside.NPJ Drug Discov2026https://conductscience.org/library/papers/42380588PubMed
42257193Synthetic Polymers for Drug, Gene, and Vaccine Delivery.Polym Sci Technol2025https://conductscience.org/library/papers/42257193PubMed
42086626Optimizing mouse models for mRNA vaccines: addressing dose translation challenges.Sci Rep2026https://conductscience.org/library/papers/42086626PubMed
41986715mRNA vaccines engage unconventional pathways in CD8+ T cell priming.Nature2026https://conductscience.org/library/papers/41986715PubMed
41962202Recent advances in LNP-mRNA vaccines.Colloids Surf B Biointerfaces2026https://conductscience.org/library/papers/41962202PubMed
41766818mRNA vaccines transform personalized lung cancer treatment.Front Immunol2025https://conductscience.org/library/papers/41766818PubMed
41586257Beginning of a new era of synthetic messenger RNA therapeutics: Comprehensive insights on mRNA drug design, development and applications.Exp Biol Med (Maywood)2025https://conductscience.org/library/papers/41586257PubMed
41535643The mRNA-Based Innovative Strategy: Progress and Challenges.Nanomicro Lett2026https://conductscience.org/library/papers/41535643PubMed
41479562mRNA-Based Personalized Cancer Vaccines: Opportunities, Challenges and Outcomes.Acta Naturae2025https://conductscience.org/library/papers/41479562PubMed
41295541Current Status and Challenges of Vaccine Development for Seasonal Human Coronaviruses.Vaccines (Basel)2025https://conductscience.org/library/papers/41295541PubMed
41150434Health Technology Assessment of mRNA Vaccines: Clinical, Economic, and Public Health Implications.Vaccines (Basel)2025https://conductscience.org/library/papers/41150434PubMed
40952557mRNA Vaccines in Cancer Immunotherapy: Recent Advances, Clinical Translation, and Future Perspectives.Curr Med Sci2025https://conductscience.org/library/papers/40952557PubMed
40905915Using modified mRNA for cardiomyocyte proliferation and cardiac genetic disease modelling and treatment.Biochem Soc Trans2025https://conductscience.org/library/papers/40905915PubMed
40881859Unraveling the potential: mRNA therapeutics in oncology.Front Oncol2025https://conductscience.org/library/papers/40881859PubMed

See all 228 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/8325342

GET https://conductscience.org/api/papers/v1/8325342/cited_by?page=2